PMID- 36533974
OWN - NLM
STAT- MEDLINE
DCOM- 20230420
LR  - 20231121
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 41
IP  - 4
DP  - 2023 Apr
TI  - Anti-neutrophil cytoplasmic antibody patterns can predict clinical relapse in 
      ANCA-associated vasculitis: overall population and subgroups.
PG  - 848-855
LID - 10.55563/clinexprheumatol/087jdd [doi]
AB  - OBJECTIVES: In anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), 
      relapses are cause of concern as they are unpredictable and predictors of poor 
      prognosis. We aimed to assess the characteristic and predictors of clinical 
      relapse in AAV. METHODS: This retrospective study included 132 cases of AAV newly 
      diagnosed from January 2016 through November 2021 in the Affiliated Hospital of 
      Qingdao University. We reviewed clinical data of patients and analysed the risk 
      factors for clinical relapse of overall population and subgroups by univariate 
      and multivariate regression models and the K-M survival curve was plotted. 
      RESULTS: The rate of relapse was highest in the positive conversion group than 
      the others significantly (p<0.001). In overall population, ANCA patterns 
      (p<0.001; persistent positive pattern: HR=3.352, 95%CI 1.463~7.678, p=0.004; 
      positive conversion pattern: HR=4.760, 95%CI 2.094~10.820, p<0.001) and 
      infections (HR =4.684, 95%CI 1.980~11.079, p<0.001) were significantly associated 
      with clinical relapse. In myeloperoxidase (MPO)-AAV patients, ANCA patterns 
      (p=0.001; persistent positive pattern: HR=4.495, 95%CI 1.508~13.396, p=0.007; 
      positive conversion pattern: HR=7.404, 95%CI 2.652~20.671, p<0.001) and 
      infections (HR=3.594, 95%CI 1.511~8.547, p=0.004) were significantly associated 
      with clinical relapse. In renal involvement patients, ANCA patterns (p=0.004; 
      persistent positive pattern: HR=3.618, 95%CI 1.364~9.592, p=0.01; positive 
      conversion pattern: HR=4.492, 95%CI 1.778~11.352, p<0.001) and infections 
      (HR=7.791, 95%CI 2.511~24.174, p<0.001) were significantly associated with 
      clinical relapse, but were not in patients without renal involvement. 
      CONCLUSIONS: Persistently positive and re-positive ANCA and infections predict 
      clinical relapse in AAV, especially in patients with MPO-AAV and renal 
      involvement. Regular ANCA monitoring should be carried out in high-risk 
      populations.
FAU - Jiang, Chunhui
AU  - Jiang C
AD  - Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Liu, Jun
AU  - Liu J
AD  - Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Wang, Huifang
AU  - Wang H
AD  - Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Liu, Hang
AU  - Liu H
AD  - Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Fu, Zixuan
AU  - Fu Z
AD  - Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Li, Min
AU  - Li M
AD  - Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Liu, Xuemei
AU  - Liu X
AD  - Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China. liuxuemei@qdu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20221215
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - EC 3.4.21.76 (Myeloblastin)
RN  - EC 1.11.1.7 (Peroxidase)
SB  - IM
MH  - Humans
MH  - *Antibodies, Antineutrophil Cytoplasmic
MH  - Retrospective Studies
MH  - Myeloblastin
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications
MH  - Recurrence
MH  - Peroxidase
MH  - Chronic Disease
EDAT- 2022/12/20 06:00
MHDA- 2023/04/20 06:41
CRDT- 2022/12/19 09:32
PHST- 2022/07/27 00:00 [received]
PHST- 2022/10/20 00:00 [accepted]
PHST- 2023/04/20 06:41 [medline]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/19 09:32 [entrez]
AID - 19039 [pii]
AID - 10.55563/clinexprheumatol/087jdd [doi]
PST - ppublish
SO  - Clin Exp Rheumatol. 2023 Apr;41(4):848-855. doi: 
      10.55563/clinexprheumatol/087jdd. Epub 2022 Dec 15.